Schmitt G, Scherer E, von Essen C F
Strahlentherapie. 1985 Dec;161(12):784-6.
The results of neutron and neutron boost irradiation of 199 patients with soft tissue sarcomas treated between 1978 and 1983 are presented. The median follow-up period is 42 months. The recurrence free survival rates by last review are 93% for patients with T1 tumours (n = 14), 87% for T2 tumours (n = 84) and 73% for T3 tumours (n = 101). The actuarial survival rates at six years are 77% for T1, 63% for T2 and 34% for T3 tumours (p = 0.018). The actuarial survival rate for the group of patients irradiated after surgery without clinical evidence of residual tumour is 63.8% compared with 30.9% for the group of patients with measurable tumour volume at the beginning of radiotherapy (p = 0.002). The survival rates according to grading are 52% for patients with G1 tumours (n = 44), 54% for G2 tumours (n = 130) and 36% for G3 tumours (n = 25). The morbidity rate of 22% after full neutron irradiation was reduced to 15% by the introduction of a neutron boost. At the present time, the results of this modified treatment are not inferior to a full neutron course. The effectiveness of neutron or neutron boost irradiation in the postoperative treatment of soft tissue sarcomas will be evaluated in a forthcoming EORTC trial.
本文介绍了1978年至1983年间接受治疗的199例软组织肉瘤患者的中子及中子增强照射结果。中位随访期为42个月。末次复查时，T1期肿瘤患者（n = 14）的无复发生存率为93%，T2期肿瘤患者（n = 84）为87%，T3期肿瘤患者（n = 101）为73%。T1、T2和T3期肿瘤患者6年的精算生存率分别为77%、63%和34%（p = 0.018）。术后照射且无残留肿瘤临床证据的患者组精算生存率为63.8%，而放疗开始时肿瘤体积可测量的患者组为30.9%（p = 0.002）。根据分级，G1期肿瘤患者（n = 44）的生存率为52%，G2期肿瘤患者（n = 130）为54%，G3期肿瘤患者（n = 25）为36%。全中子照射后的发病率为22%，通过引入中子增强照射降至15%。目前，这种改良治疗的结果并不逊于全中子疗程。在即将开展的欧洲癌症研究与治疗组织（EORTC）试验中将评估中子或中子增强照射在软组织肉瘤术后治疗中的有效性。
